Program
Anti-HER2 Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A251
Its studies are led by HUTCHMED.
Furthest: phase 2, since Nov 11, 20251 company-led study, 1 open or runningNext primary completion: Nov 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 11 open or running | phase 2since Nov 11, 2025 | Nov 11, 2025 | Nov 30, 2028phase 2 · NCT07228247 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2025First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07228247 · 147 planned · United States, China
Ahead
- Nov 30, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07228247
TargetBeta
ERBB2 →read by rule
“An antibody-targeted therapy conjugate (ATTC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the receptor tyrosine kinase human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07228247Solid Tumors, Adult · United States, China | 2 | Recruiting | Nov 30, 2028 | 147 |
How it is read
Names in the registry
- “HMPL-A251”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.